VOTIS Subdermal Imaging Technologies

Company Overview

Snapshot

Founded in June 2017 by Merrill Weber, VOTIS Subdermal Imaging Technologies operates with 11–50 employees. The company has raised $8.07 million across 6 funding rounds from 2 investors. In May 2022, VOTIS announced the enrollment of the first human subject in a pilot feasibility study for its PedCheck device at Hadassah Medical Center in Jerusalem.

Business overview

VOTIS Subdermal Imaging Technologies develops medical devices aimed at preserving the feet of individuals suffering from peripheral artery disease (PAD). Its product suite includes PedCheck for screening asymptomatic patients, PedStage for monitoring disease progression and treatment impact, and PedFlo for real-time blood flow assessment during revascularization procedures. These noninvasive, radiation-free devices serve the health tech and life sciences sectors, focusing on diagnostics and digital healthcare solutions for clinics and hospitals.

Strategic signal

In May 2022, VOTIS Subdermal Imaging Technologies announced the enrollment of the first human subject in a pilot feasibility study for its PedCheck device at Hadassah Medical Center in Jerusalem. This milestone signals significant progress in the clinical validation of their diagnostic technology for peripheral artery disease, moving their innovative solutions closer to market and demonstrating a commitment to rigorous testing and development.

Company Intelligence Q&A

What is VOTIS Subdermal Imaging Technologies' primary focus?

VOTIS Subdermal Imaging Technologies focuses on developing devices to assess foot patency in people with Peripheral Artery Disease (PAD), aiming to preserve feet through early detection and monitoring.

When was the company founded and by whom?

VOTIS Subdermal Imaging Technologies was founded in June 2017 by Merrill Weber.

What was a key development for the company in May 2022?

In May 2022, VOTIS Subdermal Imaging Technologies announced the enrollment of the first human subject in a pilot feasibility study of its PedCheck device at Hadassah Medical Center in Jerusalem.

What strategic partnership did VOTIS announce in December 2020?

In December 2020, VOTIS Subdermal Imaging Technologies and ii Ventures announced plans to develop preventative medicine devices to screen for peripheral artery disease in India.

What technology licensing agreement did VOTIS secure in October 2020?

In October 2020, VOTIS Subdermal Imaging Technologies licensed imaging technology from Columbia University.